Articles tagged with Acromegaly
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
Researchers have developed an AI-driven facial recognition system called AcroFace that can detect acromegaly by analyzing facial photographs. The system achieved a success rate of 93% in a preliminary trial, outperforming previous attempts. Early detection could lead to timely treatment and improved outcomes for patients with this rare...
A new study by The Endocrine Society finds a strong link between acromegaly and an increased risk of various cancers, often at younger ages than expected. Patients with the rare growth hormone disorder had higher rates of certain types of cancer, including colon, gastric, breast, lung, ovarian, prostate, and blood cancers.
A nationwide clinical study has demonstrated the use of biomarkers for predicting treatment effectiveness in acromegaly, enabling personalized therapies that increase success rates to 80%. This breakthrough aims to diagnose and treat the disease earlier, improving patient outcomes.
A phase 3 clinical trial found that oral octreotide capsules effectively control symptoms of acromegaly in adults without pain or lost workdays. The treatment has the potential to expand options for patients beyond injectables.
Acromegaly is usually caused by a non-cancerous tumor in the pituitary gland, leading to excessive growth hormone production and various health complications. The Endocrine Society recommends surgery as the primary therapy for most patients, offering an opportunity to examine the tumor sample and immediately lower growth hormone levels.
Acromegaly, a condition caused by pituitary gland disorders, has seen improvements in diagnosis and treatment due to advances in medical technology and medication. Effective control of the disorder is now possible for many patients, reducing negative implications such as tissue damage and hormone imbalance.
Researchers found that achieving basal growth hormone levels of less than 2.5 µg/liter and glucose-suppressed GH levels of less than one µg/liter may not minimize cardiovascular risks in acromegaly patients. Instead, these patients are at increased risk for conditions like hypertension, diabetes, and osteoarthritis.
A new study published in The Lancet reveals that pegvisomant normalized IGF-I concentrations in 97% of patients with acromegaly after 12 months of treatment. Patients experienced improved symptoms and a better quality of life, highlighting the potential benefits of this innovative drug.